Neuroimaging and other biomarkers for Alzheimer's disease: The changing landscape of early detection

Shannon L. Risacher, Andrew J. Saykin

Research output: Contribution to journalReview articlepeer-review

82 Scopus citations


The goal of this review is to provide an overview of biomarkers for Alzheimer's disease (AD), with emphasis on neuroimaging and cerebrospinal fluid (CSF) biomarkers. We first review biomarker changes in patients with late-onset AD, including findings from studies using structural and functional magnetic resonance imaging (MRI), advanced MRI techniques (diffusion tensor imaging, magnetic resonance spectroscopy, perfusion), positron emission tomography with fluorodeoxyglucose, amyloid tracers, and other neurochemical tracers, and CSF protein levels. Next, we evaluate findings from these biomarkers in preclinical and prodromal stages of AD including mild cognitive impairment (MCI) and pre-MCI conditions conferring elevated risk. We then discuss related findings in patients with dominantly inherited AD. We conclude with a discussion of the current theoretical framework for the role of biomarkers in AD and emergent directions for AD biomarker research.

Original languageEnglish (US)
Pages (from-to)621-648
Number of pages28
JournalAnnual Review of Clinical Psychology
StatePublished - Mar 2013


  • cerebrospinal fluid (CSF)
  • functional MRI (fMRI)
  • genetics
  • magnetic resonance imaging (MRI)
  • mild cognitive impairment (MCI)
  • positron emission tomography (PET)
  • preclinical Alzheimer's disease (AD)

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Fingerprint Dive into the research topics of 'Neuroimaging and other biomarkers for Alzheimer's disease: The changing landscape of early detection'. Together they form a unique fingerprint.

Cite this